Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes

To evaluate, using post hoc analyses, whether the novel combination of a basal insulin, insulin degludec, and a glucagon‐like peptide‐1 receptor agonist, liraglutide (IDegLira), was consistently effective in patients with type 2 diabetes (T2D), regardless of the stage of T2D progression.

[1]  S. Gough,et al.  One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial , 2015, Diabetes, obesity & metabolism.

[2]  S. Gough,et al.  Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. , 2014, The Lancet Diabetes and Endocrinology.

[3]  H. Rodbard,et al.  Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) , 2014, Diabetes Care.

[4]  S. Bain,et al.  Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials , 2014, Diabetes Therapy.

[5]  Domján Andrea,et al.  World Medical Association Declaration of Helsinki (WMA) - Ethical principles for medical research involving human subjects , 2014 .

[6]  G. Keating.  Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus , 2013, Drugs.

[7]  K. Khunti,et al.  A retrospective cohort study of more than 80,000 people , 2013 .

[8]  L. Boulanger,et al.  Assessing achievement and maintenance of glycemic control by patients initiating basal insulin , 2012, Current medical research and opinion.

[9]  K. Khunti,et al.  Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice , 2012, Diabetes, obesity & metabolism.

[10]  B. Bode.  An overview of the pharmacokinetics, efficacy and safety of liraglutide. , 2012, Diabetes research and clinical practice.

[11]  M. Peyrot,et al.  Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[12]  J. Dale,et al.  Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study. , 2010, Primary care diabetes.

[13]  World Medical Association (WMA).  Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects , 2009, Journal of the Indian Medical Association.

[14]  R. Rubin,et al.  Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. , 2005, Diabetes care.

[15]  Y. Yoshitoshi.  [Obesity and metabolism]. , 1967, Nihon Ishikai zasshi. Journal of the Japan Medical Association.